Top

next chapter Case II: Micro Platform, Major Innovation—WeCha...

Hint

Swipe to navigate through the chapters of this book

2018 | OriginalPaper | Chapter

Case I: 3DMed: An R&D Platform for Personalised Precision Anti-cancer Drugs

Author: Xiaoming Zhu

Publisher: Springer Singapore

Published in: China's Technology Innovators

» Get access to the full-text

Abstract

In 2010, Xiong Lei, a Ph.D. graduate from the Institute of Biochemistry and Cell Biology, SIBCB, CAS, left his post-doctoral research in the University of Zurich to found 3DMed with five other senior professionals, aiming to substantially improve R&D efficiency and approval rates of anti-cancer drugs and deliver highly effective clinical treatment for cancer. The new company is headquartered in the Shanghai Caohejing Hi-Tech Park, where over 140 biomedical start-ups are planning their business roadmaps. The question now is how 3DMed, which had completed two rounds of financing by May 2014, will achieve the expected performance and leverage talent, marketing and capital management, as well as strategic planning, to address the challenges it faces in the early stage of business development as well as to minimise innovation risks in an emerging industry.

Please log in to get access to this content

To get access to this content you need the following product:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 69.000 Bücher
über 500 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Umwelt
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Testen Sie jetzt 30 Tage kostenlos.

inform now

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 58.000 Bücher
über 300 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Testen Sie jetzt 30 Tage kostenlos.

inform now

Jemal et al. [ 1].

Chen [ 2].

American Cancer Society [ 3].

DeSantis et al. [ 4].

Berkrot [ 5].

Pammolli et al. [ 6].

Mao and Chen [ 7].

Lu et al. [ 8].

Moffat et al. [ 9].

Deng [ 10].

U.S. Food and Drug Administration, “The Drug Development Process” (24 June 2015), FDA, http://www.fda.gov/forpatients/approvals/drugs/default.htm, last accessed on 27 October 2015.

Roche [ 11].

Paul et al. [ 12].

IMS Institute, “Global Oncology Trend Report: Innovation in Cancer Care and Implications for Health Systems”, IMS Reports, May 2014.

Wang [ 13].

Li [ 14].

“R&D Investment by U.S. Biopharmaceutical Companies Reached Record Levels in 2010”, PhRMA, 15 March 2011.

CFDA Southern Medicine Economic Research Institute: Blue Book on Chinese Pharmaceutical Market Development 2010, 29 October 2010.

Shi [ 15].

Yu [ 16]

Zhu [ 17].

Yang [ 18].

Xu [ 19].

Liu [ 20].

Wang [ 21].

[US] Naisbitt [ 22].

Chen [ 23], Zhou and Liu [ 24].

Wang and Baorui [ 25].

“2003 Release: International Consortium Completes HGP”, National Human Genome Research Institute, 14 April 2003.

Luo [ 26], Sun et al. [ 27].

Calvo et al. [ 28].

Sherman et al. [ 29], Subramanian et al. [ 30].

“2003 Release: International Consortium Completes HGP”, National Human Genome Research Institute, 14 April 2003.

Gangwar and Worabo [ 31].

McLeod and Evans [ 32].

Han and Yang [ 33].

Liu [ 34], Herper [ 35].

Sharma et al. [ 36].

Wang and Wang [ 37].

Jemal A, Bray F, Center MM et al (2011) Global Cancer Statistics. Oncol Radiother (Feb)

Chen W. Chinese Cancer Registry Annual Report 2013, Chinese Cancer Registry Center, 14 Apr 2014

American Cancer Society (2010) Cancer facts & figures 2010. American Cancer Society, Atlanta

DeSantis CE et al (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64:252–271 CrossRef

Berkrot B (2011) Success rates for experimental drugs falls: study. Reuters (14 February)

Pammolli F, Magazzini L, Riccaboni M (2011) The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discovery 10

Mao K, Chen D. The history of anti-cancer drug R&D. Shanghai Technology Inquiry and Consulting Center, CAS, 22 Feb 2012

Lu Y, Chen D, Xiong Y (2012) Analysis of R&D situation of anti-cancer drugs. Chin Bull Life Sci 6

Moffat JG, Rudolph J, Bailey D (2014) Phenotypic screening in cancer drug discovery—past, present and future. Nat Rev Drug Discovery 13:588–602 CrossRef

10.

Deng Z (2013) Overview of new drug development process. Sci Monthly 2

11.

Roche. From Idea to Medicine—Drug Development at Roche. Roche Global, 2 Jan 2013

12.

Paul SM et al (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discovery (March)

13.

Wang B. Research on competitive strength of Chinese Biopharmaceutical Industry, 2010 edition published by Shanghai University of Finance & Economics Press

14.

Li P. Identifying Future Competitive Trends from Global Anti-Cancer Drug Sales Ranking. Global Oncology Express, April 2014-110

15.

Shi J. AstraZeneca Opens an Innovation Centre with Huge Investment. Xinmin Evening News, 23 Mar 2007

16.

Yu D. Roche Launches China’s First Comprehensive Clinical Trial Centre. The Economic Observer, 31 Oct 2007

17.

Zhu Q (2009) Lilly’s Unique R&D System. CEIBS Bus Rev 7

18.

Yang J. Johnson & Johnson Establishes an R&D Centre in Shanghai as Its Asia Pacific R&D Headquarters. Science and Technology Daily, 23 Apr 2009

19.

Xu H. Novartis Invests USD 1 Billion to establish China’s largest drug R&D centre. Economic Daily, 24 Nov 2009

20.

Liu C. Ding Jian: Chinese pharmaceutical companies lack anti-cancer drug R&D capability. China Science Daily, 12 June 2012

21.

Wang J. Branded drugs perform better than generic drugs. Wen Wei Po, 30 Apr 2014

22.

Naisbitt J (2009) China’s megatrends (trans: Wei P). China Industry & Commerce Associated Press in 2009

23.

Chen S (2013) Somatic mutation and novel strategies for personalized targeting therapy. J Zhejiang Univ 42(1)

24.

Zhou H, Liu J (2011) Gene targeting tailored therapy for the anti-tumor drugs. Anti-Tumor Pharm 1

25.

Wang K, Liu B (2012) Truly personalized medicine to combat cancer. Medicine & Philosophy (Clinical Decision Making Forum Edition) 6

26.

Luo B (2003) Application progress of pharmacogenomics. Chin J Pract Med 19

27.

Sun H, Ouyang W, Sun J (2004) Trend in research of pharmacogenomics in foreign countries. Chin J New Drugs 3

28.

Calvo KR, Liotta LA, Petricoin EF (2005) Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep 25(1–2)

29.

Sherman RE et al (2013) Expediting drug development—the FDA’s new ‘breakthrough therapy’ designation. N Engl J Med 369:1877–1880 (14 Nov)

30.

Subramanian R, Sheppard T, Rubin B, Kramer C (2013) FDA’s new breakthrough therapy designation: what does it mean for pricing and market access? OBR Green, Sept 2013, vol 7 (8)

31.

Gangwar SK, Worabo B (2011) Amazing facts about human DNA and genome. Society for Science and Nature, 20 Sept 2011

32.

McLeod HL, Evans WE (2001) Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 41:101–121 CrossRef

33.

Han C, Yang SC (2005) High throughput screening assay and application. Biotechnol Bull 2

34.

Liu L (2012) Illumina: the ‘Apple’ that disrupts the gene sequencing sector (2 July 2012), Instrument Information Website, http://www.instrument.com.cn/news/20120702/079802.shtml. Last accessed 3 Nov 2015

35.

Herper M (2011) The No. 1 Winner in DNA Sequencing: Illumina (5 Jan) (trans: Yu B). Forbes China, http://www.forbeschina.com/review/201101/0006529.shtml. Last accessed 3 Nov 2015

36.

Sharma SV, Haber DA, Settleman J (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 10:241–253 CrossRef

37.

Wang H, Wang Q (2014) Application of and prospect for targeted capture with the first generation of sequencing technology in the study of hereditary hearing loss. J Audiol Speech Pathol 5

Title

Case I: 3DMed: An R&D Platform for Personalised Precision Anti-cancer Drugs

Book

China's Technology Innovators

Print ISBN: 978-981-10-5387-0

Electronic ISBN: 978-981-10-5388-7

https://doi.org/10.1007/978-981-10-5388-7

DOI

https://doi.org/10.1007/978-981-10-5388-7_1

Author:

Xiaoming Zhu

Publisher

Springer Singapore

Sequence number

Premium Partner

Image Credits